JPRN-jRCT2080220194未知2 期
ate phase II study of weekly paclitaxel (BMS-181339) in patients with advanced head and neck cancer
Bristol-Myers K.K.0 个研究点目标入组 36 人开始时间: 2005年12月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •1. Patients with locally advanced head and neck cancer pretreated with surgery and/or radiotherapy and not suitable for further radical local treatment or patients with distant metastases, and measurable disease(lesion(s) with largest diameter of 10 mm or more). 2. Age range of 20 years and older to less than 75 years. 3. Performance Status : 0 - 2
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck CancerHead and Neck CancerNCT00855764Bristol-Myers Squibb36
已完成
2 期
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck CancerHead and Neck CancerNCT01024101Bristol-Myers Squibb36
已完成
2 期
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT01024062Bristol-Myers Squibb60
已完成
2 期
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast CancerBreast CancerNCT01023204Bristol-Myers Squibb68
已完成
2 期
A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapyAdvanced or recurrent esophageal cancerJPRN-UMIN000019230niversity of Miyazaki Hospital25